Skip to main content
Amoy Diagnostics Co.,Ltd. logo

Amoy Diagnostics Co.,Ltd. — Investor Relations & Filings

Ticker · 300685 ISIN · CNE1000034D3 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,089 across all filing types
Latest filing 2019-02-13 Major Shareholding Noti…
Country CN China
Listing Shenzhen Stock Exchange 300685

About Amoy Diagnostics Co.,Ltd.

https://www.amoydx.com

Amoy Diagnostics Co., Ltd. specializes in the development and commercialization of molecular diagnostic products for precision oncology. The company provides a comprehensive portfolio of testing kits designed to identify genetic mutations and biomarkers essential for personalized cancer treatment. Its core technology platforms include the proprietary ADx-ARMS, Super-ARMS, and specialized Next-Generation Sequencing (NGS) solutions. AmoyDx focuses on companion diagnostics (CDx), collaborating extensively with global pharmaceutical companies to integrate diagnostic testing into clinical drug development and patient management. Key products cover a wide range of solid tumors, including lung, colorectal, and breast cancers, facilitating targeted therapy selection and monitoring. The company maintains rigorous quality standards, with numerous products receiving regulatory approvals for clinical use in multiple international markets.

Recent filings

Filing Released Lang Actions
关于特定股东股份减持计划时间届满并拟继续减持公司股份的公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the expiration of a specific shareholder's stock reduction plan and the intention to continue reducing shares. It details the shareholder's name, shareholding percentages before and after reduction, reduction methods, periods, and compliance with relevant laws and regulations. The document does not contain financial statements or detailed financial performance data but focuses on shareholding changes and reduction plans. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels. The document length is 3241 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2019-02-13 Chinese
关于持股5%以上股东股份减持计划时间过半的进展公告
Major Shareholding Notification Classification · 95% confidence The document is an announcement regarding the progress of a shareholding reduction plan by a shareholder holding more than 5% of the company's shares. It details the number of shares reduced, the method of reduction, dates, prices, and the shareholder's holdings before and after the reduction. It explicitly states it is a progress announcement about a shareholding reduction plan and includes compliance statements about legal and regulatory adherence. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement about a major shareholder's transaction in shares, specifically a reduction in holdings. This fits the category of Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels crossing thresholds. The document length is 2508 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is MRQ with high confidence.
2019-02-13 Chinese
关于使用部分闲置募集资金进行现金管理的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from a company regarding the use of idle raised funds for cash management. It details the approval by the board and supervisory committee, the amount of funds involved, investment purpose, risk control measures, and opinions from independent directors and the sponsor institution. The document does not contain financial statements or detailed financial performance data but is a regulatory disclosure about the company's financing fund usage and management. It is not an annual or interim report, audit report, or earnings release. It is also not a proxy, voting result, or management change announcement. The document fits best as a Capital/Financing Update (CAP) because it concerns the use and management of raised capital funds and related approvals and disclosures.
2019-02-11 Chinese
独立董事关于相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on various company matters including the appointment of a senior executive, approval of a 2019 restricted stock incentive plan, assessment of performance targets, use of idle raised funds for cash management, and changes in fundraising project payment methods. It references compliance with company law, securities law, and stock exchange regulations, and discusses governance and management decisions. The content is focused on board/management decisions and governance-related opinions rather than financial results, earnings, or regulatory filings. The document length is 2882 characters, which is relatively short and does not contain financial statements or earnings data. It is not a report publication announcement since it contains substantive opinions and approvals. The document fits best under Board/Management Information (MANG) as it relates to management appointments and governance decisions by the board and independent directors.
2019-02-11 Chinese
2019年限制性股票激励计划实施考核管理办法
Board/Management Information Classification · 95% confidence The document is titled as the "2019 Restricted Stock Incentive Plan Implementation Assessment Management Measures" for Xiamen Aide Biomedical Technology Co., Ltd. It details the governance, assessment principles, scope, and procedures related to the company's restricted stock incentive plan. The content focuses on the management and evaluation of a stock incentive plan, including performance targets and assessment mechanisms for executives and key personnel. There is no indication that this is a financial report, earnings release, or regulatory filing. Instead, it relates to management and board-level information about stock incentives and governance mechanisms. This fits best under Board/Management Information (MANG), which covers announcements about changes or policies related to company management and board-level decisions. The document is not a report of financial results or a regulatory filing but a management policy document regarding stock incentives.
2019-02-11 Chinese
2019年限制性股票激励计划（草案）摘要
Remuneration Information Classification · 95% confidence The document is a detailed plan titled "厦门艾德生物医药科技股份有限公司 2019 年限制性股票激励计划（草案）摘要" which translates to "Xiamen Aide Biological Pharmaceutical Technology Co., Ltd. 2019 Restricted Stock Incentive Plan (Draft) Summary." It extensively discusses the company's stock incentive plan, including the purpose, legal basis, management, scope of incentive recipients, stock quantity, allocation, effective period, grant price, conditions for granting and lifting restrictions, performance targets, and adjustment methods. The document references relevant laws and regulatory bodies such as the China Securities Regulatory Commission and Shenzhen Stock Exchange. It is a comprehensive disclosure of a stock incentive plan, which is a form of remuneration information related to executive and key personnel compensation. It is not an annual report, audit report, earnings release, or any other financial report type. It is not a brief announcement but a full detailed plan document. Therefore, the most appropriate classification is Remuneration Information (DEF 14A), which covers detailed compensation plans for executives and directors, including stock incentive plans.
2019-02-11 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.